Literature search services are currently unavailable. During our hosting provider's UPS upgrade we experienced a hardware failure and are currently working to resolve the issue.

Preparing your results

Our searching services are busy right now. Your search will reload in five seconds.

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Role of the polycomb repressive complex 2 in acute promyelocytic leukemia.

Epigenetic changes are common alterations in cancer cells. Here, we have investigated the role of Polycomb group proteins in the establishment and maintenance of the aberrant silencing of tumor suppressor genes during transformation induced by the leukemia-associated PML-RARalpha fusion protein. We show that in leukemic cells knockdown of SUZ12, a key component of Polycomb repressive complex 2 (PRC2), reverts not only histone modification but also induces DNA demethylation of PML-RARalpha target genes. This results in promoter reactivation and granulocytic differentiation. Importantly, the epigenetic alterations caused by PML-RARalpha can be reverted by retinoic acid treatment of primary blasts from leukemic patients. Our results demonstrate that the direct targeting of Polycomb group proteins by an oncogene plays a key role during carcinogenesis.

Pubmed ID: 17560333


  • Villa R
  • Pasini D
  • Gutierrez A
  • Morey L
  • Occhionorelli M
  • VirĂ© E
  • Nomdedeu JF
  • Jenuwein T
  • Pelicci PG
  • Minucci S
  • Fuks F
  • Helin K
  • Di Croce L


Cancer cell

Publication Data

June 11, 2007

Associated Grants


Mesh Terms

  • Carrier Proteins
  • Cell Differentiation
  • DNA Methylation
  • Epigenesis, Genetic
  • Gene Silencing
  • Granulocytes
  • Histones
  • Humans
  • Leukemia, Promyelocytic, Acute
  • Nuclear Proteins
  • Oncogene Proteins, Fusion
  • Polycomb Repressive Complex 2
  • Polycomb-Group Proteins
  • Repressor Proteins
  • Tretinoin
  • Tumor Cells, Cultured